Medicine
Cardiolite 1 mg/mL powder for injection
Cardiolite 1 mg/mL powder for injection is a prescription medicine containing Tetrakis(2-methoxyisobutylisocyanide)copper(i) tetrafluoroborate for intravenous use, marketed by Shine Spect, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 15-25°C (59-77° F) before and after reconstitution.
Key facts
- Active ingredient (INN)
- Tetrakis(2-methoxyisobutylisocyanide)copper(i) tetrafluoroborate
- Brand
- Cardiolite
- Strength
- 1 mg/mL
- Dosage form
- Powder for injection
- Route
- Intravenous
- Packs
- 20 vials, 5 vials and 1 more
- Marketing authorisation holder
- Shine Spect
- Manufacturers
- Shine SpectLantheus Medical Imaging
- Origin register
- US FDA, United States
- Storage
- Store at 15-25°C (59-77° F) before and after reconstitution.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 20 December 1990
- Identifiers
- DailyMed set ID 773b6729-2a74-49e7-9215-ca70da3b854c, 49662def-2fb9-47b2-8467-ca56f6006167NDC 87333-001, 11994-001Application NDA019785
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 20 vial in 1 box / 5 mL in 1 vial | 87333-001-20 | Shine Spect | 10 September 2026 |
| 5 vial in 1 box / 5 mL in 1 vial | 87333-001-55 | Shine Spect | 10 September 2026 |
| 20 vial in 1 box / 5 mL in 1 vial | 11994-001-20 | Lantheus Medical Imaging | 28 February 2008 |
| 5 vial in 1 box / 5 mL in 1 vial | 11994-001-55 | Lantheus Medical Imaging | 20 December 1990 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Tetrakis(2-methoxyisobutylisocyanide)copper(i) tetrafluoroborate 1 mg/mL powder for injection.
Other strengths and forms of Tetrakis(2-methoxyisobutylisocyanide)copper(i) tetrafluoroborate
Clinical summary
Tetrakis(2-methoxyisobutylisocyanide)copper(i) tetrafluoroborate is a prescription medicine indicated for detecting coronary artery disease by localizing myocardial ischemia (reversible defects) and infarction (non-reversible defects) evaluating myocardial function and developing information for use in patient management decisions Myocardial Imaging. MedsAcross supplies Tetrakis(2-methoxyisobutylisocyanide)copper(i) tetrafluoroborate for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Tetrakis(2-methoxyisobutylisocyanide)copper(i) tetrafluoroborateFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Cardiolite prescribing information (Shine Spect) · U.S. National Library of Medicine, DailyMed
Need Cardiolite 1 mg/mL powder for injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.